IntroDuctIon
Understanding the genetic and cellular origins of human prostate cancer is a primary focus of interventional inquiry. Human prostate cancer is commonly regarded as a disease of luminal cell origin on the basis of pathological evidence and immunohistochemical markers. Recent findings, however, complicate the picture and suggest that basal stem-like cells are potential cells of origin [1] [2] [3] . The unique ability to self-renew suggests that tissue stem cells may serve as a likely origin of multiple cancers, making these cells intriguing targets for investigative research and therapeutic intervention 4, 5 . Therefore, delineating the epithelial hierarchy and purifying specific cell types from prostate and other tissues based on functional characteristics will help researchers to examine the cellular contexts and genetic influences undermining epithelial transformation.
Overview of the procedure
This protocol describes how to prepare, purify and transform defined populations of primary human prostate epithelial cells, and has been recently used by us to identify a cell of origin for human prostate cancer 2 . A sequential enzymatic digestion of primary tissue yields a total dissociated cell preparation containing all the cell types present in the original tissue, with the sole exception of red blood cells, which are removed by a specific lysis step. We use fluorescence-activated cell sorting (FACS) techniques to purify immune and epithelial cell subsets. This approach allows for the simultaneous isolation of distinct cell populations. Other methodologies to purify epithelial progenitor cells rely on differential centrifugation and/or preferential adhesion of specific cell types to extracellular matrices such as collagen 6, 7 . These protocols may be useful to enrich for epithelium or purify distinct subpopulations, but they leave other cells behind, whether they are stroma or stem cell-depleted epithelial cell types. In contrast to magnetic bead separation, FACS provides precise control to purify cells that express high, intermediate or low levels of multiple antigens. We have used this strategy for the purification of human prostate epithelial progenitor cells that form spheres 8 , tubules and malignant structures resembling prostate cancer 2 , while also allowing the simultaneous isolation and discrimination of the remaining epithelial and nonepithelial subsets, including immune cells.
Purified epithelial cells are transduced with lentivirus to overexpress different oncogenes and transplanted into immunedeficient mice for regeneration of benign or malignant epithelium. This strategy is analogous to transplantation approaches used to study normal and malignant development in hematopoietic and mammary cells. The major advantage of this approach is the use of naive adult human epithelial cells, which are the target cells for the disease. By directly transforming primary cells and transplanting them in vivo, this approach avoids potential artifacts introduced in tissue culture. Although the current protocol focuses primarily on human prostate epithelium, recent literature in our laboratory has made use of modified versions of this protocol in both mouse and human systems 1, 2, [8] [9] [10] .
Model systems of prostate cancer
Several model systems are used for the study of prostate cancer and the specific pathways involved in it. Cell lines and xenografts 11 are the most widespread models in the field, and they provide valuable insight into fundamental pathways and mechanisms that support the survival and growth of prostate cancer cells. As the majority of such cell lines are derived from late-stage or metastatic cancer, this model system is useful for uncovering and testing biochemical Purification and direct transformation of epithelial progenitor cells from primary human prostate epithelial cell transformation has been demonstrated in numerous animal models for the study of solid tumor biology. However, little evidence exists for human epithelial cell transformation without previous immortalization via genetic influences such as sV40 t-antigen, thus limiting our knowledge of the events that can transform naive human epithelium. Here we describe a system developed in our laboratory to directly transform freshly isolated primary human prostate epithelial cells without previous culture or immortalization. prostate tissue is obtained from patients and benign tissue is separated from malignant tissue. Benign and malignant tissues are mechanically and enzymatically dissociated to single cells overnight, and immune cells and epithelial subsets are isolated on the basis of differential expression of surface antigens. epithelial progenitor cells are transduced with lentiviruses expressing oncogenes and combined with inductive stroma for in vivo studies. at 8-16 weeks after transplantation into immune-deficient mice, the development of lesions, histologically classified as benign prostate, prostatic intraepithelial neoplasia and adenocarcinoma, can be evaluated.
mechanisms in vitro and in vivo, but is not sufficient to investigate the genetic and epigenetic alterations responsible for converting healthy tissue to a malignant state. The introduction of mouse models of prostate cancer, such as those involving the prostate-specific deletion of phosphatase and tensin homolog (Pten), the overexpression of c-Myc, and the transgenic adenocarcinoma of the mouse prostate (TRAMP) model, has allowed researchers to further understand the pathways leading to disease initiation and progression in an oncogene or pathway-dependent fashion [12] [13] [14] . However, development of these murine models requires complex breeding strategies and multiple crosses that are time consuming, expensive and do not allow parallel studies with human tissue. The approach described here allows researchers to introduce oncogenes, via lentivirus, into primary prostate epithelial cells for transplantation under the kidney capsule or skin of immune-deficient mice. This technique measures both the regenerative and tumorigenic capacity of isolated prostate cell types 1, 9 .
Although the prostate regeneration model takes cells out of their natural microenvironment and requires organogenesis concomitant with tumorigenesis, the system is faster and cheaper than mouse breeding studies, allows efficient testing of multiple oncogene combinations and permits parallel studies in mouse and human tissues.
Diversity of potential applications and limitations
Elucidating the pathways important for prostate stem cell function, prostate cancer initiation and castration-resistance is crucial for moving forward. As we can now routinely isolate basal and luminal cells from benign prostates as well as cancer cells from tumor issue, we can interrogate these specific cell populations using an array of genomic and proteomic approaches, including (but not limited to) microarrays, deep sequencing, activity-based protein profiling, and kinase enrichment and mass spectrometry. However, without a human prostate regeneration system, the functional relevance of these new pathways and targets cannot be tested. Hence, the ability to consistently introduce new genes of interest, discovered using existing genomic and proteomic technologies, into primary human benign cells will shed light on new avenues and opportunities for therapeutic development.
Although we are capable of using many different approaches to interrogate dissociated human prostate epithelium, we are limited by the frequency at which samples are obtained and the amount of tissue that is available for processing. This technique is designed for use in situations where prostate tissue can be readily transferred to the appropriate laboratory for immediate processing, such as at academic institutions attached to medical centers. If prostate tissue needs to be shipped or stored for long periods of time, the cell yield and viability may be greatly reduced.
Experimental design
In vivo regeneration. The subrenal regeneration assay, described in Box 1, is technically demanding and requires experience to perfect the procedure. Before using valuable human materials, we recommend practicing the technique with mouse prostate epithelium. If preferred, subcutaneous implantation of these cells may be performed, as described in Box 2. Using sorted cells, we have found that the rate of outgrowth formation is generally higher in the subcutaneous site compared with kidney capsule engraftment. The subcutaneous injection is an easier procedure and allows the monitoring of graft size through the skin. However, the reproducibility may be lower in the subcutaneous grafts because of the lack of blood supply, which is more abundant and consistent in the kidney capsule 15 .
Fluorescence-activated cell sorting. Sorting time should be arranged in advance at your institutional core facility to ensure that cells can be sorted on the same day that the tissue is processed. Two types of controls are vital for accurate cell sorting, single color controls and fluorescence minus one (FMO) controls. Control tubes should be set up such that cells are stained with one fluorescent antibody at a time. This will allow you to determine the bleed-over for each fluorophore into each channel and set the appropriate voltage compensation. FMO is a strategy that involves leaving out one fluorescent antibody at a time to ensure that positive staining is indeed due to that specific antibody. FMO analysis should be performed when testing an antibody or setting up the gates for the first time.
Box 1 | SUBRENAL REGENERATIoN ASSAY • tIMInG 2-3 h
For the sake of completeness and ease of implementing the procedure, the information provided here has been reproduced and adapted from a previous protocol in which we described implanting primary epithelial cell grafts under the kidney capsule for in vivo regeneration 10 . 1. Anesthetize a male immune-deficient mouse with the appropriate anesthetic, such as ketamine/xylazine (see REAGENT SETUP), approved by national and institutional regulations. Once the animal is anesthetized, place the mouse in prone position and shave a 3 cm × 3 cm area in the mid-back region. Sterilize the surgical area by alternating iodine and alcohol prep swabs three times. ! cautIon All experiments involving live rodents must conform to the national and institutional standards and regulations. 2. Cut a small incision in the skin around the middle of the back, ~1 cm lateral to the spine. Cut a small hole in the exposed peritoneum. 3. Hold the peritoneum open using forceps and search for the kidney. Once it has been located, use the small fat pad located at the tip of the kidney to pull it to the surface and out above the skin. 4. Gently grab the thin membrane on the outside of the kidney with two forceps and tear a small hole. Lift the edge of the capsule and push the collagen graft underneath the membrane. One to four collagen grafts can be inserted per kidney capsule depending on the size of the kidney.  crItIcal step Make sure the collagen plug is secure underneath the kidney capsule. 5. Grab the peritoneum with forceps, and gently allow the kidney to slip back into the body. Make sure the graft does not slip out. Suture the peritoneum together, taking care not to puncture any organs. Insert a testosterone pellet subcutaneously, as described in step 4 of Box 2. Finally, use metal clips to staple the skin closed. 6. Monitor and medicate the mice in accordance to national and institutional animal care protocols. Remove staples 7 d after surgery.
Functionality of Matrigel. Lot-to-lot variation exists in the functional ability of Matrigel to induce sphere formation in vitro and/or tubule formation in vivo. Testing of each specific lot before the experiment is crucial to avoid wasting valuable sample materials. We suggest plating ~5,000 or 10,000 enriched prostate basal cells in Matrigel to induce sphere formation, as has been previously described 10 . A good lot of Matrigel will support robust sphere formation in as little as 5 d. Growth factor-reduced Matrigel has not been tested with human prostate cells.
Importance of urogenital sinus mesenchyme. Urogenital sinus mesenchyme (UGSM) cells are derived from the developing urogenital sinus, the site of prostate gland formation. This fetal stroma creates a highly inductive environment by secreting specific growth factors important for prostate tubule formation and development. In contrast, stromal cells isolated from the adult prostate provide growth factors that are primarily involved in maintaining tissue homeostasis. In the absence of UGSM, the prostate epithelial cells are prone to form undifferentiated cord-like structures rather than well-differentiated tubules. Mouse UGSM is sufficient to support human prostate regeneration; however, prostate development may be enhanced with the addition of species-specific factors through the use of parallel human fetal stroma. As human fetal stroma is difficult to obtain, we are currently testing mixtures of inductive mouse UGSM with human stromal cells, such as immortalized or primary benign and carcinoma-associated fibroblasts 7 , to support human prostate epithelial growth and regeneration.
An alternative approach to using syringes for cell dissociation. The use of syringes with unscreened human material is very dangerous and represents a potential biohazard. To avoid the use of sharps during cell dissociation (PROCEDURE, Step 12), the plunger from a 10-ml syringe can be used to mash the tissue either onto a 10-cm tissue culture dish or through a mesh strainer. Alternatively, the digested tissue can be dissociated by pipetting up and down using a plastic micro pipette tip. These alternative methods of dissociation reduce potential hazards, but are less efficient at recovering epithelial cells.
Antibody dilutions.
We highly recommend empirically determining the antibody concentration needed for efficient labeling of the cells. The dilutions outlined in this protocol are recommended as a starting point in this process.
Box 2 | SUBCUTANEoUS INJECTIoN • tIMInG 2-3 h
For the sake of completeness and ease of implementing the procedure, the information provided here has been reproduced and adapted from a previous protocol in which we described subcutaneous injection of primary epithelial cell grafts for in vivo regeneration 10 . 1. Anesthetize a male immune-deficient mouse with the appropriate anesthetic such as ketamine/xylazine (see REAGENT SETUP) approved by national and institutional regulations. Once the animal is anesthetized, place the mouse in the prone position and shave the back of the mouse. Sterilize the target injection site by alternating iodine and alcohol prep swabs three times. ! cautIon All experiments involving live rodents must conform to the national and institutional standards and regulations. 2. Immediately before injection, gently pipette to mix the 30-µl cell mixture in 1.7 ml microcentrifuge tube on ice. Draw up the mixture into an insulin syringe, making sure to avoid bubbles. 3. Using a clean pair of forceps, pull up the freshly shaved and cleaned skin of the mouse, creating a tent between the skin and musculature of the flank. Inject the mixture, and pull out the needle slowly. Hold onto the skin using the forceps for a minute to make sure the Matrigel has settled. 4. Implant a testosterone pellet subcutaneously in mice to ensure an environment with excess androgen: make a small incision through the outer layer of skin, implant the pellet and staple the wound in the skin using metal clips. 5. Monitor and medicate the mice in accordance to national and institution animal care protocols. Remove staples 7 d after the procedure.
MaterIals

REAGENTS
Prostate tissue: obtained by surgery from the Pathology Department, as described in Box 3 ! cautIon All experiments involving human tissues must conform to relevant national and institutional standards and regulations. UGSM, prepared as described in ). Pass the medium through 0.22-µm filter to sterilize. We highly recommend preparing this solution fresh each time. However, any excess can be stored at − 20 °C for up to 2 weeks. Prostate epithelial cell growth medium (PrEGM) PrEBM basal medium is supplied with nine pre-aliquotted supplements (bovine pituitary extract, insulin, hydrocortisone, GA-1000, retinoic acid, transferrin, triiodothyronine/T3, epinephrine, and recombinant human epidermal growth factor). On receipt, PrEBM medium is stored at 4 °C and supplements are stored at − 20 °C. Thaw nine frozen supplements and add all to PrEBM basal medium to yield PrEGM. Filter to sterilize. Store PrEGM in dark bottle for up to 3 weeks at 4 °C or divide into 50 ml aliquots and freeze at − 20 °C for long-term storage of up to 2 months.
Box 3 | PREPARATIoN oF TISSUE FRoM RoBoTIC RADICAL PRoSTATECToMY SURGERY AND PAThoLoGY
Following institutional review board approval, patients scheduled to undergo radical prostatectomy (robot-assisted laparoscopic radical prostatectomy (RALP) or open radical retropubic prostatectomy (RRP)) are consented for research participation to collect blood and prostate tissue. After an overnight fast, patients are brought to the operating room where general anesthesia is administered and a standard RALP or RRP is performed. The pathology department is contacted just before removal of the specimen to facilitate immediate transportation of fresh tissue to the pathology laboratory for subsequent analyses.  crItIcal step Although every attempt is made to standardize the surgical procedure, it should be noted that differences in surgeon, surgical technique, intraoperative variables and operative time may all affect the time at which the specimen is sent for analysis. As a result, tissue hypoxia times may vary considerably between specimens.
The prostate is transported to the surgical pathology laboratory at room temperature (25 °C) as soon as it is removed from the patient. A trained and licensed pathology assistant weighs and measures the prostate, inks its surface with India ink (to assess the status of surgical margins on histological sections) and slices the prostate from base to apex. Under an institutional review boardapproved protocol, slices 2 and 4 of the prostate are used for research, whereas the rest is entirely submitted for pathological diagnosis. Slices 2 and 4 are divided into four quadrants, and additional ink of different colors is used for orientation indicating right versus left and anterior versus posterior. The procured tissue is separated into top and bottom portions with a knife, keeping enough tissue on the top for frozen section diagnosis while preserving as much fresh tissue in the bottom as possible. Tissue from the top is snap-frozen, and a frozen section slide is prepared and stained with a hematoxylin and eosin-based protocol. The pathologist examines the frozen section slides under the microscope and circles the cancerous and benign areas. The fresh tissue (bottom portion) is then matched with the frozen section slides and the cancerous and benign areas are separated manually. Care is taken to ensure that benign regions are free of cancer; however, cancerous regions will regularly contain surrounding benign areas. ) and insulin to a final concentration of 25 µg ml − 1 to 440 ml DMEM basal medium. Store at 4 °C for up to 1 month. Trypsin (1% (vol/vol)) Dilute the 10% trypsin to 1% (vol/vol) in sterile 1× PBS. Prepare a fresh, small aliquot each time. Do not store. Trypan blue mix (1:4) Dilute 10 ml of 0.4% (vol/vol) trypan blue into 30 ml of 1× PBS to obtain a total of 40 ml mixture. Ketamine/xylazine Add 100 µl of 100 mg ml -1 xylazine and 300 µl of 100 mg ml -1 ketamine to 2.25 ml 1× PBS. Filter to sterilize. Mix well before injecting into mice (approximately 7 µl per g of mouse body weight).
Box 4 | URoGENITAL SINUS MESENChYME (UGSM) PREPARATIoN • tIMInG 16 D PLUS 7-8 h
UGSM cells are essential for proper in vivo regeneration. For the sake of completeness and ease of implementing the procedure, the information provided here has been reproduced and adapted from a previous protocol in which we described the preparation of UGSM cells 10 .
Set up matings for timed pregnancies. Euthanize pregnant female mice at E16 (embryonic day 16 of pregnancy).
! cautIon All experiments involving animals must conform to the national and institutional standards and regulations. 2. Take the uterus with the embryos, and move it to a 10-cm dish containing DMEM complete digestion medium. Cut the uterus laterally, separate embryos from the placenta, and place them in a fresh dish containing DMEM complete digestion medium. 3. Cut embryos in half, below the liver. Place the bottom half of the embryos into a new dish containing sterile 1× PBS. Place the bottom half of the embryos in a supine position and cut the abdomens open while holding the hind legs apart with forceps. 4. The urogenital sinus (UGS) is connected to the bladder. As in the adult, the urogenital sinus can be removed intact by gently pulling the bladder up. Dissect the pelvic UGS, clean the attached tubular structures and cut the bladder. 5. Place the pelvic UGS onto a concave glass slide containing 250 µl DMEM complete digestion medium. When each UGS has been collected, wash all tissues three times with 1× PBS. Aspirate the last wash of PBS carefully, and add 1 ml of 1% (vol/vol) trypsin. Keep the plate in 4 °C for 90 min to allow digestion. 6. Carefully remove the trypsin using a pipette and add DMEM complete digestion medium. Carefully pipette the media off and add 1 ml of DMEM complete digestion medium containing 500 U of DNase I. Set aside for 5 min. 7. Wash the UGS three more times with fresh DMEM complete digestion medium. 8. After the third wash, take two 28-G needles and separate the mesenchyme away from the epithelium. The epithelium can be identified as the opaque cylinder-shaped object inside the more translucent and vascular mesenchyme. 9. Collect all the mesenchyme fragments into a 15-ml Falcon tube containing 10 ml of collagenase/dispase digestion solution. Digest at 37 °C for 2 h with rocking action on an Adams Nutator Mixer. 10. After digestion, filter the cells through a nylon mesh filter with 40-µm pore size and wash the filter with 10 ml of DMEM complete digestion medium. Spin down cells at 1,300 r.p.m. (400g) at 25 °C for 5 min. Aspirate the medium and resuspend cells in 10 ml UGSM medium. Plate in a 10-cm tissue culture dish. 11. Culture for 5-7 d and monitor cell growth. Passage and expand the UGSM cells when they get to 80% confluency.  crItIcal step Do not passage UGSM cells more than five times, as they lose their inductive capacity in later passages.  pause poInt UGSM cells can be frozen down and stored at − 80 °C or in liquid nitrogen for up to 6 months. proceDure Weighing and preparing tissue for overnight enzymatic digestion • tIMInG 1 h 1| Obtain tissue samples from a pathology laboratory (Fig. 1a) . Trim marked regions of tissue with scissors (Fig. 1b) and measure the weight of unmarked tissue in grams (Fig. 1c) . Transfer tissue to a 100 mm × 20 mm tissue culture dish (Fig. 1d) . ! cautIon All work with primary human tissue must be carried out in an approved tissue culture hood with proper attire, including PPE, and all relevant ethical guidelines and regulations must be followed.
2|
Use scissors to cut tissue into small chunks. Add a small amount of PBS to keep tissue together and continue to cut until chunks are small enough to pass through a 5-ml pipette. Transfer the tissue chunks/PBS mixture to a 50-ml conical tube using a 5-ml pipette and wash the tissue culture dish with additional PBS as needed. 
5|
While centrifuging, prepare the collagenase/dispase digestion solution (see REAGENT SETUP). Calculate the total volume needed (10 ml per g of tissue and up to 50 ml for 5 g in a single 50-ml conical tube).
6| Aspirate supernatant from tissue in
Step 4 and resuspend in the collagenase/dispase digestion solution. For >5 g of starting tissue, the digestion process will need to be carried out in multiple 50 ml conical tubes.  pause poInt If samples are processed earlier in the day, then tissue can be kept on ice or at 4 °C until the end of the day in DMEM complete digestion solution, before overnight digestion at 37 °C in the collagenase/dispase digestion solution. 12| Aspirate supernatant, resuspend in 10 ml of DMEM complete digestion solution. Draw the cells/medium mixture up and down through an 18-G needle attached to a 10-ml syringe up to five times. Repeat with 20-and 22-G needles if possible. ! cautIon The use of sharps around unscreened human biological material is very dangerous. Please take extra care when using syringes in this manner. An alternative approach to using sharps is discussed in Experimental design. 
17|
Aspirate the supernatant and resuspend the cell pellet in 1-3 ml PrEGM complete medium. Count cells by hemocytometer to determine the yield (Fig. 1f) . Approximately 5 million total cells can be regularly collected per g of starting tissue.  pause poInt Dissociated cells can be stored on ice or at 4 °C for several hours before sorting, depending on the availability of the FACS instrument. (Fig. 2) . Collect cells in 1 ml of 50% PrEGM/50% FBS. ! cautIon Sorting can create an aerosol. All sorting of human cells should be carried out in vacuum.
30|
Spin down cells at 1,800 r.p.m. (754g) for 5 min at 4 °C. Aspirate the supernatant and resuspend in 1 ml of PrEGM.  pause poInt Sorted cells can be stored on ice before counting and infection. For other types of analysis, including protein, RNA or DNA, sorted cell pellets or lysates can be stored at − 80 °C for the long term.
31| Mix 10 µl of the cells in PrEGM with 10 µl of 1:4 trypan blue mix, and count the sorted prostate epithelial cells by hemocytometer. Viable healthy cells exclude the blue dye. This assay can be used to determine the degree of viability in a sample. Set aside a subset of sorted cells as the control sample for the transduction efficiency assay described in Box 5. If less than 20% of target cells are transduced, experiments will be difficult to interpret. We suggest that 20% transduction efficiency is the minimal acceptable level for proceeding with the experiment. ! cautIon Lentivirus is highly infectious and the use of third-generation lentiviral vectors is highly recommended (Fig. 3) . All lentivirus is pseudotyped with VSV-g for efficient transduction using either mouse or human cells.
33|
Add Polybrene to each tube at a final concentration of 8 µg ml − 1 (include the amount needed for lentivirus into the calculated total volume).
34|
Add the appropriate high-titer lentivirus to the tube in a typical multiplicity of infection in the range of 25-75, as determined by infection on 293T cells 17 . ! cautIon All experiments involving lentivirus must conform to institutional regulations and appropriate PPE must be worn at all times.
35|
Place the tubes at 37 °C in a sterile tissue culture incubator, designated for lentivirus only, for 1 h making sure to mix the tubes every 15 min by flicking. 17 for more detailed information on this system and how to efficiently produce high-titer lentivirus.
38| Aspirate the supernatant and place cell pellet on ice. To prepare Matrigel grafts, follow option A. Prepare collagen grafts according to option B.  pause poInt Grafts can be kept in a standard tissue culture incubator at 37 °C overnight before surgery the following day. (Fig. 4a) or transformation (Fig. 4b) can be analyzed by staining paraffin-embedded tissue with hematoxylin and eosin and with human prostate luminal cell markers such as prostate-specific antigen. Normal regenerated tubules (Fig. 4c) 
